Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company's platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal's immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company's advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:NVET
- CUSIP: N/A
- Web: www.nexvet.com
- Market Cap: $78.03 million
- Outstanding Shares: 11,752,000
- 50 Day Moving Avg: $6.17
- 200 Day Moving Avg: $4.39
- 52 Week Range: $2.75 - $6.76
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.91
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.22 per share
- Price / Book: 2.99
- EBIDTA: ($19,080,000.00)
- Return on Equity: -57.98%
- Return on Assets: -50.99%
- Current Ratio: 7.69%
- Quick Ratio: 7.69%
- Average Volume: 71,360 shs.
- Beta: 0.52
- Short Ratio: 7.24
Frequently Asked Questions for Nexvet Biopharma plc (NASDAQ:NVET)
What is Nexvet Biopharma plc's stock symbol?
Nexvet Biopharma plc trades on the NASDAQ under the ticker symbol "NVET."
How were Nexvet Biopharma plc's earnings last quarter?
Nexvet Biopharma plc (NASDAQ:NVET) announced its earnings results on Thursday, May, 11th. The company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.02. View Nexvet Biopharma plc's Earnings History.
Where is Nexvet Biopharma plc's stock going? Where will Nexvet Biopharma plc's stock price be in 2017?
1 brokers have issued 12-month target prices for Nexvet Biopharma plc's shares. Their predictions range from $6.72 to $6.72. On average, they expect Nexvet Biopharma plc's stock price to reach $6.72 in the next year. View Analyst Ratings for Nexvet Biopharma plc.
Who are some of Nexvet Biopharma plc's key competitors?
Some companies that are related to Nexvet Biopharma plc include Vascular Biogenics Ltd (VBLT), Mediwound Ltd (MDWD), Fate Therapeutics (FATE), Uniqure NV (QURE), Conatus Pharmaceuticals (CNAT), Oncomed Pharmaceuticals (OMED), Evogene Ltd (EVGN), Pluristem Therapeutics (PSTI), MannKind (MNKD), 22nd Century Group (XXII), Sorrento Therapeutics (SRNE), BioDelivery Sciences International (BDSI), Arrowhead Pharmaceuticals (ARWR), ProQR Therapeutics NV (PRQR), Adverum Biotechnologies (ADVM), CTI BioPharma Corp (CTIC), VIVUS (VVUS) and CymaBay Therapeutics (CBAY).
When did Nexvet Biopharma plc IPO?
(NVET) raised $58 million in an initial public offering (IPO) on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.
Who owns Nexvet Biopharma plc stock?
Nexvet Biopharma plc's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
FARALLON CAPITAL MANAGEMENT LLC
(26.80%), Broadfin Capital LLC (9.59%), Foresite Capital Management II LLC (7.46%) and Boxer Capital LLC (1.32%). Company insiders that own Nexvet Biopharma plc stock include Ashraf Hanna, Cormac G Kilty, David Gearing and Farallon Capital Management Ll. View Institutional Ownership Trends for Nexvet Biopharma plc.
Who sold Nexvet Biopharma plc stock? Who is selling Nexvet Biopharma plc stock?
How do I buy Nexvet Biopharma plc stock?
Shares of Nexvet Biopharma plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Nexvet Biopharma plc stock cost?
One share of Nexvet Biopharma plc stock can currently be purchased for approximately $6.64.
Earnings History for Nexvet Biopharma plc (NASDAQ:NVET)Earnings History by Quarter for Nexvet Biopharma plc (NASDAQ:NVET)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Nexvet Biopharma plc (NASDAQ:NVET)
Current Year EPS Consensus Estimate: $-1.79 EPS
Next Year EPS Consensus Estimate: $-1.70 EPS
Dividend History for Nexvet Biopharma plc (NASDAQ:NVET)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nexvet Biopharma plc (NASDAQ:NVET)
Insider Ownership Percentage: 37.00%Insider Trades by Quarter for Nexvet Biopharma plc (NASDAQ:NVET)
Institutional Ownership Percentage: 48.68%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/4/2016||David Gearing||Insider||Buy||11,113||$3.33||$37,006.29|| |
|3/2/2016||Ashraf Hanna||Director||Buy||1,500||$3.20||$4,800.00|| |
|2/26/2016||Farallon Capital Management Ll||Insider||Buy||435,000||$3.19||$1,387,650.00|| |
|2/24/2016||Cormac G Kilty||Director||Buy||3,000||$3.17||$9,510.00|| |
|9/10/2015||Farallon Capital Management Ll||Insider||Buy||11,100||$6.46||$71,706.00|| |
|9/9/2015||Cormac G Kilty||Director||Buy||10,000||$4.79||$47,900.00|| |
|2/10/2015||One Funds Management Ltd Atf A||Major Shareholder||Buy||100,000||$10.00||$1,000,000.00|| |
Headline Trends for Nexvet Biopharma plc (NASDAQ:NVET)
Latest Headlines for Nexvet Biopharma plc (NASDAQ:NVET)
Nexvet Biopharma plc (NVET) Chart for Thursday, May, 25, 2017